Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
FDA expanded EVO/EVO+ age indication, preliminary Q1 sales exceeded $90M with China rebound and Americas growth, Q1 results due 2026-05-13, and shares remain up about 32% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profitability Rebound ⢠Strong Liquidity ⢠Elevated Valuation STAA's profitability, cash flow, and liquidity have improved sharply, but severe prior-year losses and elevated valuation temper the investment case.
Price Behavior
Key Price Behavior Insights: ⢠Weakening Momentum ⢠Support Holding ⢠Resistance Overhead Support Level: $22.66â$22.86 Resistance Level: $24.64â$24.66; $25.33â$26.18 STAA remains weak after a roughly 12% drop from $26.18, with support at $22.66â$22.86 and recovery potential only if it reclaims $24.66.
Sentiment & News
Key News Insights: ⢠Earnings Beat ⢠China Growth ⢠CEO Transition STAAR Surgical delivered a strong Q2 2026 beat, powered by surging China and Asia-Pacific sales, while new CEO Warren Foust and positive analyst sentiment support its growth outlook.
AI Summary
STAAR's strong quarter reflects China-driven shipment normalization more than proven global demand, making sustained ex-China growth and repeatable cash generation essential to justify its demanding valuation.
Description
STAAR Surgical Company designs, manufactures and sells implantable intraocular lenses and the delivery systems used to place them, along with preloaded cataract lenses, injector components and related surgical instruments. Its products, which address refractive errors and cataract treatment, are marketed primarily to ophthalmologists and surgical centers through a mix of direct sales forces and distributor networks across North America, Europe and Asia. The company was founded in 1982 and is headquartered in Lake Forest, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | STAA | STAAR Surgical Company | FDA expanded EVO/EVO+ age indication, preliminary Q1 sales exceeded $90M with China rebound and Americas growth, Q1 results due 2026-05-13, and shares remain up about 32% over 21 trading days. | Closed | +5.9% |
| Apr 10 | Apr 17 | STAA | STAAR Surgical Company | STAAR Surgical has a fresh revenue surprise and momentum: preâannounced Q1 net sales above ~$90M drove a ~25% twoâday spike, and FDA expansion of EVO/EVO+ ICL indication (21â60 years) broadens its market. Shares are ~42% above their 21âday mean, with strong volume and activist/institutional buying, making STAA a highâvelocity nearâterm trade around the formal earnings release. | Closed | -5.1% |